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ABSTRACT 
Biological effects of rutin bioactive are limited due to its poor oral bioavailability and its degradation in aqueous 
environments. For the purpose of bioenhancement, different nanoemulsion systems of rutin were developed by 
aqueous titration method using water as dispersion media. The nanoemulsion systems were characterized for sur-
face morphology, droplet size, polydispersity index, zeta potential, in vitro release profile and the formulations 
were optimized. The anticancer potential of optimized nanoemulsion was evaluated by cells viability (MTT) assay, 
nuclear condensation, and ROS activity using human prostate cancer (PC3) cell line. On the basis of cell viability 
data the inhibitory concentration (IC50) value for optimized nanoemulsion formulation on PC3 cancer cells was 
found to be 11.8 μM. Fluorescent microscopic analysis and intracellular ROS generation demonstrated significant 
ROS induction that might lead to triggering the apoptosis pathway. In conclusion, developed nanoemulsion dis-
played significant efficacy against prostate carcinoma cells. 
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INTRODUCTION 
Cancer chemoprevention using bioactive 
compounds has attracted increasing attention 
in recent years (Liu, 2013; Surh, 2003). Bio-
active compounds with anticancer properties 
alone or in combinations with other potent 
synthetic molecules are used to prevent or re-
verse the processes of carcinogenesis, further-
more to minimize the undesirable side effects, 
which are commonly associated with current 
therapies (Pan and Ho, 2008). Several bio-fla-
vonoids found to be effective in in vitro stud-
ies at a particular concentration, often exhibit 
lower responses at a higher concentration as 
revealed by in vivo studies (Scalbert et al., 
2005; Amidon et al., 1995). Many factors 
such as gastric residence time, permeability, 
and solubility within the gut and some other 
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factors also direct the bioavailability of bio-
flavonoid. Gastrointestinal pH, enzymes, and 
presence of other nutrients sometimes also in-
fluence the stability of these bioactives. Poor 
aqueous solubility and low dissolution rates 
of flavonoids contribute to their insufficient 
bioavailability (Kaur and Kaur, 2014). Rutin 
was first prepared and identified from the 
plant Ruta graveolens L. (Rutaceae) by Au-
gust Weiss, a pharmacist-chemist of Nurem-
berg, Germany in 1842. So its name comes 
from the name of plant Ruta graveolens, a 
species of Ruta grown as an ornamental plant 
commonly known as rue or herb of grace 
(Biçer and Özdemir, 2014; Couch et al., 
1946). Rutin (quercetin-3-O-rutinoside) is 
abundantly found in dietary foods such as 
grains, fruits (especially in citrus fruits) and 
berries (Macedo et al., 2014; Ghiasi et al., 
2012; Krewson and Couch, 1950). Rutin from 
buckwheat was isolated by Schunck in 1860 
and afterward chemists found rutin in a num-
ber of plants. Rutin was first medicinally used 
for the management of increased capillary fra-
gility, a condition in which the smallest blood 
vessels become abnormally fragile and rup-
ture, so that small hemorrhages occur. The 
correction of the capillary fault is known as 
the "vitamin P" action.  According to the sci-
entist James F. Couch, rutin might possess a 
"vitamin P" action. The term “Vitamin P” had 
been postulated in 1936 by a Hungarian bio-
chemist, Albert Szent-Györgyi, to account for 
certain medical effects produced by citrus ex-
tracts that could not be explained by reference 
to ascorbic acid or vitamin C (Grzybowski 
and Pietrzak, 2013; Couch, 1951; Krewson 
and Couch, 1950). Various studies conducted 
both in vitro and in vivo suggest the diverse 
pharmacological activities of rutin bioactive 
including anticancer properties (Naif Abdul-
lah Al-Dhabi et al., 2015; Sharma et al., 2013; 
Lin et al., 2009). Due to the poor bioavailabil-
ity, the oral use of rutin is limited and subse-
quently higher doses  are required to achieve 
the  desired anticancer effect. It appears that 
only about 17 % of an ingested dose is ab-
sorbed (Marzouk et al., 2007). 
For the purpose of bio-enhancement of 
drug action, various approaches including 
nano emulsification, solid dispersions, micro-
emulsions, and development of solid-lipid 
nanostructures have been undertaken. Nano-
emulsification serves as a  means to improve 
the oral bioavailability of lipophilic com-
pounds as well as their ability to improve drug 
solubility, membrane transport, and absorp-
tion via the lymphatic system with bypassing 
first pass metabolism (Gupta et al., 2013). 
Nanoemulsion offers several advantages over 
the conventional drug delivery systems in-
cluding higher solubilization capacity, rapid 
onset of action, reduced inter-subject differ-
ences (Rahman et al., 2011). The nanoemul-
sions can thus be defined as thermodynami-
cally stable, transparent (or translucent) dis-
persions of oil and water stabilized through an 
interfacial film of surfactant molecules hav-
ing a droplet size less than 100 nm. The de-
velopment of effective formulation for drugs 
has long been a major subject, because drug 
efficacy can be strictly limited by instability 
and poor solubility in the vehicle. Nanoemul-
sions have a higher solubilization capacity 
than conventional micellar solutions. Ther-
modynamic stability of nanoemulsions offers 
advantages over unstable dispersions, such as 
emulsions and suspensions, because they can 
be manufactured by applying very little en-
ergy input (heat or mixing) and have a long 
shelf life. Nanoemulsions are also reported to 
make the plasma profiles and bioavailability 
of many drugs highly reproducible (Lawrence 
and Rees, 2012; Eccleston, 1994). 
Cancer is an increasing health problem 
worldwide; however, prostate carcinoma is 
the most common cancer in man and the sec-
ond leading cause of death in many countries 
(Kumar et al., 2006; Ullen et al., 2005). 
Hence, novel therapies are required for the 
treatment of advanced prostate cancer and to 
improve patient compliance. Selection of the 
suitable in vitro techniques in cancer research 
is critical for the evaluation of various ge-
netic, epigenetic and cellular changes. Addi-
tionally, the application of the cell line models 
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already exists as a part of the ongoing re-
search on cancer therapy (Louzada et al., 
2012). Cell line models are very useful tools 
for the measurement of mediators such as pro-
liferation deregulation, apoptosis and cancer 
progression (Vargo-Gogola and Rosen, 
2007). To date there are 4 well studied Human 
Prostate Cancer cell lines. They are DU145, 
PC3, LNCaP and TSU-PnI. Out of all these 
PC3 cell line is easily available and shows 
most similar progression as that of human 
prostate cancer.  The PC3 and DU145 human 
prostate cancer cell lines are representative of 
the earlier type-I ADI prostate cancers. PC3, 
but not DU145 cells retain the coregulators 
needed for AR tumor suppressor ability of an-
drogen receptor (Litvinov et al., 2006). 
In the present study we selected PC3 cell 
line of human prostate carcinoma to evaluate 
the antiproliferative potential of the devel-
oped rutin nanoemulsion. 
 
MATERIALS AND METHODS 
Chemicals and reagents 
Propylene glycol monocaprylate (Capryol 
90) and caprylocaproyl macrogol-8-glyceride 
(Labrasol) (Gattefosse, Gennevilliers, 
France) were gift samples from Colorcon 
Asia (Mumbai, India), while propylene glycol 
monocaprylic ester (Sefsol 218) and Kolli-
phor RH-40 were a gift sample from Nikko 
Chemicals (Tokyo, Japan) and BASF, Mum-
bai, respectively. Diethylenemonoglycol 
ether (Carbitol), Polyethylene Glycol (PEG-
200, 400, 600), Isopropyl myristate (IPM), 
glycerol triacetate (Triacetin), methanol 
(HPLC-Grade), and Distilled Water were pur-
chased from E-Merck (Mumbai, India). Poly-
oxyethylene sorbitan monolaurate (Tween-
20), polyoxy ethylene sorbitan monostearate 
(Tween-60), polyoxyethylene sorbitan mono-
oleate (Tween-80), ethanol, isopropyl alcohol 
were procured from S.D. Fine Chemicals 
(Mumbai, India). Fluorescent dye 2,7-dichlo-
rodihydrofluorescein diacetate (DCFH-DA) 
and 4',6'-diamidino-2 phenylindole (DAPI) 
were purchased from Sigma Aldrich, USA. 
Eagle’s minimal essential medium (MEM), 
fetal bovine serum (FBS), MTT (3 (4,5-dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) dye and antibiotic solutions were 
purchased from Himedia, India. Rutin (97 %) 
bioactives were purchased from Sigma-Al-
drich Chemical Company (St. Louis, Mis-
souri). All the reagents used for study were of 
analytical grade. 
 
Cell line and culture 
Human prostate adenocarcinoma (PC3) 
cell line was procured from National Centre 
for Cell Sciences (NCCS), Pune, India. PC3 
cells were maintained in MEM medium sup-
plemented with 2.0 mM L-glutamine, 1.5 g/l 
NaHCO3, 0.1 mM non-essential amino acids, 
1.0 mM sodium pyruvate and 10 % (v/v) FBS. 
Cells were incubated at 37 °C and 5 % CO2 
incubator. 
 
Selection of excipients on the basis of  
solubility 
To find out appropriate oils, surfactants 
and co-surfactant as components of 
nanoemulsion system with high loading ca-
pacity is based on the solubility of poorly sol-
uble drug in oils, surfactants, and co-surfac-
tants, screening of component such as oils 
(middle chain, long chain and synthetic tri-
glycerides) Triacetin, Isopropyl myristate, 
Capryol-90, Sefsol 218, Olive oil including 
surfactants Tween-80, Labrasol, Kolliphor-
HS15, Kolliphor-RH40 and co-surfactants 
such as Transcutol-P, Carbitol, Polyethylene 
glycol-200, 400 and 600. An excess amount 
of drug was added in the oils and surfactants 
as well as co-surfactant and kept in isothermal 
shaker for 72 h at 25 ± 2 °C temperature to 
reach equilibrium. Finally samples were re-
moved from the shaker and centrifuged at 
3000 rpm for 15 min. The supernatant was 
taken and filtered through a 0.45 µm mem-
brane filter to remove the remaining insoluble 
drugs. Concentration of rutin was determined 
by HPLC. All the excipients selected for for-
mulation were under the GRAS (Generally 
Regarded as Safe) category. Finally excipi-
ents were selected as formulation components 
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on the basis of highest solubility of rutin in 
different excipient (Wang et al., 2009). 
 
Method of preparation of nanoemulsion 
Nanoemulsion systems were developed 
using phase titration method keeping water as 
dispersion media. Pseudoternary phase dia-
grams were constructed to represent the best 
ratio of oil, surfactant/co-surfactant (Smix), 
and water. Surfactant and co-surfactant was 
mixed (Smix) in different volume ratios (1:0, 
1:1, 1:2, 1:3, 2:1, 3:1, etc). These Smix ratios 
were chosen to reflect increasing concentra-
tions of co-surfactant with respect to surfac-
tant and increasing concentrations of surfac-
tant with respect to co-surfactant for detailed 
study of the phase diagrams in the nanoemul-
sion formation. Mixture of oil with Smix was 
prepared at different ratios (e.g. 10:0, 9:1, 8:2, 
7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9, 0:10) into dif-
ferent vials. A small amount of water in 5 % 
(w/w) increments was added into the vials. 
Following each water addition the mixture in 
vials was centrifuged for 2 to 3 minute and in-
cubated at 25 °C for 48 h with gentle shaking. 
The resulting mixtures were evaluated by vis-
ual and microscopy observation. For phase di-
agram the nanoemulsion is the region of clear 
and isotropic solution. The physical state of 
the nanoemulsion is marked on the phase dia-
grams with one axis representing aqueous 
phase, the second representing oil and the 
third representing a mixture of surfactant and 
co-surfactant (Smix) at fixed weight ratios 
(Smix ratio). The nanoemulsion area in each 
phase diagram is plotted and the wider region 
indicated the better self nanoemulsifying effi-
ciency (Singh et al., 2008). 
 
Construction of pseudoternary phase  
diagrams 
Pseudoternary phase diagrams were 
drawn for determining Smix ratio and its ratio 
with oil phase in emulsion system which 
gives the nanoemulsion region (Figure 1). On 
the basis of solubility and compatibility of ru-
tin with various excipients, Kolliphor RH-
40/Labrasol//PEG-200, 400, 600 was selected 
as the surfactant, PEG-200, 400, 600 as co-
surfactant and Sefsol218/Isopropyl myrsitate 
were selected as the oil phase. For every phase 
diagram, oil and accurate Smix ratio was mixed 
in volume ratios ranging from 1:9 to 9:1 to ob-
tain sixteen different combinations like 1:9, 
1:8, 1:7, 1:6, 1:5 1:4, 1:3.5, 1:3, 3:7, 1:2, 4:6, 
5:5, 6:4, 7:3, 8:2 and 9:1 and titrated with wa-
ter for constructing zone of nanoemulsion. 
Smix ratios 1:0, 1:1, 2:1, 1:2 and 3:1 were se-
lected from above experiments. Concentra-
tions of all the excipients used were within 
permissible limits recommended for oral us-
age. 
 
Development of drug containing  
formulations 
Nanoemulsion system was developed by 
taking best suited optimized concentrations of 
oil phase (Sefsol 218), surfactant (Kolliphor 
RH-40), and co-surfactant (PEG-400) was se-
lected from ternary phase diagrams and this 
system was then loaded with excess amount 
of rutin (10 mg/ml). Another system compris-
ing the oil phase (Isopropyl myristate), sur-
factant (Labrasol) and co-surfactant (PEG-
600) was selected from ternary phase dia-
grams and this system was then loaded with 
excess amount of rutin (10 mg/ml). These 
were subsequently sonicated for 10 minutes 
on a bath sonicator. 
 
Measurement of drug contents in 
nanoemulsion 
Finally six formulations were selected and 
the best suitable formulations amongst them 
were analyzed for the drug contents from 
nanoemulsion formulations that were ex-
tracted in methanol. The solutions were fil-
tered, using Whatman filter paper of 0.45 µm 
pore size and analyzed for the drug contents 
through HPLC. 
 
Characterization of optimized formulation 
dispersibility test 
One ml of each nanoemulsion formulation 
was added to 500 mL of distilled water and 
0.1 N HCl separately at a temperature of 
37 °C in a standard USP XXII dissolution ap-
paratus. The dissolution paddle rotated at a 
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speed of 50 rpm to provide gentle mixing. In 
vitro performance of the formulations was 
visually assessed using grading system as per 
the dispersibility comments. Formulations 
that approved the thermodynamic stability 
test and dispersibility test in Grade A as well 
as B had been chosen for additional studies 
(Akhtar et al., 2014). 
 
 
 
Figure 1: Ternary phase chart indicating o/w nanoemulsion region at different Smix ratios. (A) Isopropyl 
myristate, Smix (Labrasol and polyethylene glycol) and water, (B) Sefsol 218, Smix (Kolliphor-RH40 and 
Polyethylene glycol) and water 
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Thermodynamic stability studies 
Selected formulations were subjected to 
different thermodynamic stability tests to as-
sess their physical stability. For centrifugation 
test, a definite volume of formulations were 
diluted in (1:10-1:100 ratios) with aqueous 
medium and centrifuged at 15,000 rpm for 15 
minutes, then the formulation was observed 
visually for the phase separation. After that 
formulations were subjected to freeze thaw 
cycles between −21 °C and +25 °C, with for-
mulation storage at each temperature for not 
less than 48 h. Those formulations found to be 
thermodynamically stable were selected for 
further characterization (Shafiq-un-Nabi et 
al., 2007). 
 
Percentage transmittance 
Percentage transmittance of the prepared 
nanoemulsion was determined spectrophoto-
metrically after 100 times dilution with meth-
anol using Shimadzu UV-visible spectropho-
tometer keeping distilled water as a blank. 
 
Droplet size and zeta potential analysis 
The droplet size and the size distribution 
of the prepared nanoemulsion systems were 
determined using Zetasizer (Nano ZS, Mal-
vern Instruments, U.K). For the purpose of 
particle size different dilution were made and 
each sample was analyzed in triplicate at a 
temperature, 20 °C and refractive index, 1.4. 
Zeta potential was also measured by photon 
correlation spectroscopy. The prepared nano-
emulsions with and without dilution were an-
alyzed using double distilled water.  
 
Transmission electron microscopy (TEM) 
Details on the morphology and other 
structural features of the nanoemulsion for-
mulations were viewed using Transmission 
Electron Microscope (TEM), Model EM-410 
LS facility available at USIF, AMU, Aligarh 
(India). Prior to the analysis, the samples were 
diluted at 10-100 times with water and ap-
plied on the grids which were stained with 
2 % (w/v) phosphotungstic acid for 30 s and 
then grids were observed after drying, using 
combination of bright field imaging at in-
creasing magnification to reveal the form and 
size of nanoemulsion droplets (Shafiq-un-
Nabi et al., 2007). 
 
Viscosity 
Viscosity of the selected formulations 
were determined at 25 ± 0.5 °C by Brookfield 
Viscometer DV III ultra V6.0 RV cone and 
plate rheometer (Brookfield Engineering La-
boratories, Middleboro, MA) (Shafiq-un-
Nabi et al., 2007). 
 
In vitro drug release study 
Comparative in vitro release profile of the 
optimized nanoemulsion and the pure drug 
suspension in phosphate buffer (pH 6.8), 0.1 
N HCl (pH 1.2) and distilled water were stud-
ied using dialysis bag techniques at 100 rpm 
rotational speed. The temperature was main-
tained at 37 ± 0.5 °C. Drug release was car-
ried out by placing 1 ml of nanoemulsion in 
treated dialysis bag (MWCO 14,000 g/mole, 
Sigma, USA). 0.5 mL aliquots was withdrawn 
at pre-determined time intervals (0, 0.25, 0.5, 
0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 4, 
6, 8, 12, 16, 20, and 24 h) and same volume 
was replenished with fresh dissolution media 
to maintain the sink condition. The samples 
withdrawn were filtered using 0.45 µm filter 
paper and the drug was analyzed by reported 
HPLC method (Shafiq-un-Nabi et al., 2007).  
 
In vitro cell viability assay 
To detect cell viability after treatment 
with rutin nanoemulsion, approximately 
1x104 cells/well of PC3 were seeded in 100 μl 
complete culture medium in 96-well culture 
plate and incubated overnight in humidified 
air. Stock was prepared in phosphate buffer 
saline (PBS) and diluted into culture medium 
to the desired concentrations 2, 5, 10, 15 and 
20 μM, then added to the wells. After 24 h of 
incubation period, 10 μl of MTT (5 mg/ml in 
PBS) reagent was added and re-incubated at 
37 °C until purple formazan crystals devel-
oped. Formazan blue crystals were dissolved 
in 100 μl of DMSO and read at 540 nm using 
microplate ELISA reader (BIORAD 680, 
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USA). The plot of percent cell viability versus 
nanoemulsion concentrations was used to cal-
culate the concentration lethal to 50 % of the 
cells (IC50). The cellular morphological 
changes were observed under inverted phase 
contrast microscopy (Nikon ECLIPSE Ti-S, 
Japan) (Siddiqui and Arshad, 2014). 
 
Intracellular ROS activity 
Intracellular ROS generation was ana-
lyzed by using fluorescence microscopic im-
aging technique (Siddiqui et al., 2015). Cells 
(1×104 per well) were exposed at two effec-
tive concentrations i.e. 5 and 10 μM of rutin 
nanoemulsion for 12 h. Subsequently, cells 
were incubated with DCFH-DA (10 mM) at 
37 °C for 30 min and washed with PBS. Intra-
cellular fluorescence intensity of cells was 
visualized by inverted fluorescent microscope 
(Nikon ECLIPSE Ti-S, Japan). For quantita-
tive fluorometric analysis, cells (1×104 per 
well) were seeded and treated with nanoemul-
sion in 96-well black bottom culture plate. 
Fluorescence intensity was measured with a 
multiwell microplate reader (Synergy H1 Hy-
brid Multi-Mode Microplate Reader, BioTek, 
USA) at an excitation wavelength of 485 nm 
and at an emission wavelength of 528 nm. 
Data were expressed as percentage of fluores-
cence intensity relative to the control wells. 
 
Apoptotic effect of formulation using DAPI 
stain 
Fluorescent nuclear dye was used to ana-
lyze the apoptotic effect of rutin nanoemul-
sion. PC3 cells (1×105 cells per well) were 
seeded in 24-well culture plate overnight and 
treated with rutin nanoemulsion for 24 h. Fol-
lowing incubation period, cells were washed 
and fixed in 4 % paraformaldehyde for 15 min 
followed by permeabilization with permea-
bilizing buffer (3 % paraformaldehyde and 
0.5 % Triton X-100) for 10 min. After stain-
ing with DAPI dye (50 µg/ml), images of con-
densed nuclei undergoing apoptosis were cap-
tured with an inverted fluorescent microscope 
(Nikon ECLIPSE Ti-S, Japan). Apoptosis 
was quantitated by morphological changes of 
nuclei with approximately 500 cells/well rep-
resenting one sample (Siddiqui et al., 2015). 
 
Statistical analysis  
The results were expressed as mean ± SD 
and were analyzed statistically (graph pad 
prism for Windows, version 5) using one-way 
analysis of variance (ANOVA) followed by 
Tukey’s test and considered statistically sig-
nificant when ܲ < 0.05. 
 
RESULTS AND DISCUSSION 
Preparation and characterization of 
nanoemulsion  
Pseudoternary phase diagrams were con-
structed to represent the concentration of oils, 
surfactant and co-surfactant used for the de-
velopment of appropriate formulation 
(Shafiq-un-Nabi et al., 2007). Solubility of 
Rutin in Isopropyl myristate, Sefsol 218 was 
highest among all the oils screened (Table 1). 
On the basis of solubility study Labrasol and 
Kolliphor-RH40 were selected as surfactant 
whereas polyethelene glycol 600 and poly-
ethelene glycol-400 as co-surfactant respec-
tively. Rutin nanoemulsion system (RF-13) 
contains Isopropyl myristate (IPM) as oil 
phase with Smix comprised of Labrasol and 
PEG-600 whereas another rutin nanoemul-
sion system (NRF-07) has Sefsol 218 as the 
oil phase with Smix comprising Kolliphor-
RH40 as surfactant and PEG-400 as co-sur-
factant. Nanoemulsion systems of these opti-
mized components were evaluated for the dis-
persibility, thermodynamic stability, percent-
age transmittance and droplet size analysis 
(Table 2). Thermodynamically stable systems 
are formed at a particular concentration of oil, 
surfactant and water, without any kinetic in-
stability and phase separation (Table 3 and 
Table 4). In order to develop an oral nano-
emulsion formulation, dispersibility studies 
were of great importance. Dispersibility tests 
were done to evaluate the dispersion effi-
ciency and the stability of nanoemulsion sys-
tems in the gastrointestinal fluids. On the ba-
sis of dispersibility assessment, those formul-
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Table 1: Rutin solubility in different oils, surfactants and co-surfactants 
 
Table 2: Observation for dispersibility test 
Sl. No. Grade Comments 
1. A Rapidly forming nanoemulsion, having a clear or bluish appearance 
2. B Rapidly forming, slightly less clear nanoemulsion, having a bluish white appear-
ance 
3. C Fine milky emulsion that formed within 2 min 
4. D Dull grayish white emulsion having slightly oily appearance that is slow to emul-
sify (longer than 2 min) 
5. E Formulation exhibiting either poor or minimal emulsification with large oil glob-
ules present on the surface 
 
Table 3: Thermodynamic stability studies of rutin-loaded nanoemulsion containing Isopropyl myristate 
(Oil phase), Labrasol (Surfactant) and Polyethylene glycol (Co-surfactant) 
 
F. Code Smix 
ratio  
Co-surfactant 
used 
%Oil 
 
 %Smix 
 
 %Water Thermodynamic stability tests Inference 
Centrifugation 
 
Heating
& 
Cooling 
cylce 
Freeze-
Thaw 
Cycle 
Dispersibility 
 
0.1 N 
HCl 
Distt. 
Water 
RF-01 1:0 ---- 7.02 28.07 64.91     A A Passed 
RF-02 1:1 
PEG-200 4.55 40.91 54.55 
    B A Passed 
RF-03 2:1 PEG-200 5.00 45.00 50.00    X C B Failed 
RF-04 1:2 PEG-200 3.51 31.58 64.91   X X C C Failed 
RF-05 3:1 PEG-200 3.51 31.58 64.91     B A Passed 
RF-06 1:1 PEG-400 3.51 31.58 64.91     B A Passed 
RF-07 2:1 PEG-400 4.00 36.00 60.00 X X  C B Failed 
RF-08 1:2 PEG-400 3.51 31.58 64.91    X C B Failed 
RF-09 3:1 PEG-400 5.00 45.00 50.00   X  C B Failed 
RF-10 1:1 PEG-600 2.99 26.87 70.15     B A Passed 
RF-11 2:1 PEG-600 2.99 26.87 70.15     B B Passed 
RF-12 1:2 PEG-600 3.51 31.58 64.91 X X  C B Failed 
RF-13 3:1 PEG-600 3.51 31.58 64.91     A A Passed 
Solubility in oil (mg/mL) 
Average±S.D., n=3 
Solubility in surfactant (mg/mL) 
Average±S.D. n=3 
Solubility in co-surfactant (mg/mL) 
Average±S.D. n=3 
Isopropyl 
myristate 
(IPM) 
21.35±1.64 
 
 
Labrasol 77.64±0.31 Carbitol 71.18±1.61 
Acconon 60.23±0.13 
Transcutol-P 81.37±0.63 
Sefsol 218 43.96±0.05 
 
 
Kolliphor-RH40 67.41±0.12 PEG-200 61.21±3.14 
PEG-400 84.93±2.21 
PEG-600 92.73±5.67 
Olive oil 17.54±1.30 Tween-80 73.21±0.21 Ethanol 11.82±0.14 
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Table 4. Thermodynamic stability studies of rutin-loaded nanoemulsion containing Sefsol 218 (Oil 
phase), Kolliphor-RH40 (Surfactant) and Polyethylene glycol (Co-surfactant) 
 
 
 
ations in grade A as well as in grade B had 
been selected for additional studies. The per-
centage transmittance that provides an idea 
about the size of the droplets and the droplet 
size is proportional to the percentage trans-
mittance of the formulation. Percentage trans-
mittance approaching 100 % indicates the iso-
tropicity of formulations. The percentage 
transmittance for RF-13 formulation was 
97.34 % while for NRF-07 formulation was 
found to be 96.12 % (Table 5). Upon optimi-
zation, it was observed that formulation RF-
13 and NRF-07 have mean droplet size of 
70.09 nm, 86.84 and minimum PDI 0.195, 
0.165 respectively. The zeta potential of both 
selected formulation (RF-13 and NRF-07) 
was between -15mV to -17 mV, which indi-
cated the stability of both the formulation and 
negatively charged surface of drug carrier. 
The viscosity of the selected formulations was 
in the range of 8-20 cps as expected for o/w 
nanoemulsion. Furthermore, transmission 
electron microscopy (TEM) was employed to 
evaluate the morphology and structure of the 
resulting nanoemulsion droplets. TEM study 
reveals that most of the nanoemulsion drop-
lets containing rutin were in spherical shape 
(Figure 2). 
 
In vitro drug release study  
Dialysis bag technique was used to study 
and compare the in vitro release profile of ru-
tin nanoemulsion and the plain drug. The drug 
release in 0.1 N HCl (pH 1.2), phosphate 
buffer (pH 6.8) and distilled water is shown in 
Figure 3. The results showed ~ 90 % rutin re-
lease from nanoemulsion formulation while 
pure drug suspension showed ~ 20 % in first 
2 h. The release of drug from nanoemulsion 
formulation was significantly higher (p<0.05) 
compared to pure drug suspension.  
 
 
 
 
F. Code Smix 
ratio  
Co-surfactant 
used 
%Oil 
 
 %Smix 
 
 %Water Thermodynamic stability tests Inference 
Centrifugation 
 
Heating
& 
Cooling 
cylce 
Freeze-
Thaw 
Cycle 
Dispersibility 
 
0.1 N 
HCl 
Distt. 
Water 
NRF-01 1:0 ----------- 6.15 9.23 84.62     B A Passed 
NRF-02 1:1 PEG-600 10.00 15.00 75.00     A A Passed 
NRF-03 2:1 PEG-600 17.54 17.54 64.91         X        X C A Failed 
NRF-04 1:2 PEG-600 8.96 20.90 70.15     A A Passed 
NRF-05 3:1 PEG-600 13.33 26.67 60.00 X       X  B B Failed 
NRF-06 1:1 PEG-400 8.96 20.90 70.15     A A Passed 
NRF-07 2:1 PEG-400 20.00 20.00 60.00     A A Passed 
NRF-08 1:2 PEG-400 5.56 19.44 75.00         X  B A Failed 
NRF-09 3:1 PEG-400 11.94 17.91 70.15     A A Passed 
NRF-10 1:2 PEG-200 7.49 22.47 70.04 X        X C B Failed 
NRF-11 1:1 PEG-200 8.33 16.67 75.00     A A Passed 
NRF-12 2:1 PEG-200 5.56 19.44 75.00 X        X C B Failed 
NRF-13 3:1 PEG-200 11.94 17.91 70.15     B A Passed 
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Table 5: Characterization of optimized rutin nanoemulsion systems 
F. Code Mean Droplet 
size (nm) 
Polydispersity 
index (PDI) 
Zeta potential 
(mV) 
Viscosity ± SD 
(cps) 
% Transmit-
tance 
RF-01 33.85 0.201 -2.89 10.4 ± 0.312 98.27 ± 0.11 
RF-11 88.89 0.114 -15.9 8.6 ± 0.231 96.33 ± 0.32 
RF-13 70.09 0.195 -15.9 9.3 ± 0.211 97.34 ± 0.22 
NRF-01 42.19 0.206 -6.07 8.1 ± 0.211 97.22 ± 0.21 
NRF-07 86.84 0.165 -17.9 10.7. ± 0.129 96.12 ± 0.31 
NRF-09 73.09 0.222 -23.9 11.2 ± 0.124 91.14 ± 0.21 
 
 
 
Figure 2: Surface morphology of rutin nanoemulsion systems by TEM. (a) RF-13, (b) NRF-07; Droplet 
size distribution, (c) RF-13, (d) NRF-07; Zeta-potential, (e) RF-13 and (f) NRF-07 
 
 
Figure 3: Comparative in vitro release profile of prepared nanoemulsion and rutin suspension in Phos-
phate buffer (pH 6.8); 0.1 N HCl (pH 1.2) and Distilled Water
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Effect of rutin nanoemulsion on percent 
cells viability and cell morphology 
The nanoemulsion systems were tested 
for in vitro antiproliferative activity against 
PC3 (prostate cancer) cells using MTT reduc-
tion assay. Cellular morphological changes 
were observed significantly in PC3 cells 24 h 
after the treatment of compound at different 
concentration by inverted phase contrast mi-
croscopy. Figure 4A showed that the cells 
drastically changed their morphological 
shapes to round shape in treatment groups de-
pending upon dose which is characterized by 
condensed cytoplasm, cellular shrinkage and 
clumped cells forming clusters (Kumar et al., 
2006). The cell viability data as cleared from 
Figure 4B indicates that 2 μM of nanoemul-
sion reduces the cell viability approximately 
90.14 % (p<0.05) as compared with control 
and it was dramatically reduced to approxi-
mately 73.31 % (p < 0.05) when treated with 
5 μM of rutin nanoemulsion. However, 10 μM 
of compound reduces the viability approxi-
mately 62.3 % and it was noticeably reduced 
to approximately 35.61 % (p < 0.05) at 15 μM 
of rutin nanoemulsion. Moreover, 20 μM of 
rutin nanoemulsion reduces PC3 cells viabil-
ity only 18.15 %. A similar study has shown 
the toxicity of the oligonucleotide/cationic 
nanoemulsion complexes on liver HepG2 
cells reducing cell numbers significantly 
(Fraga et al., 2008). Present results suggested 
that treatment of rutin nanoemulsion signifi-
cantly reduces the cell viability of cancer cell 
line in a dose-dependent manner. 
 
Rutin nanoemulsion induces intracellular 
ROS generation 
As observed from Figure 5A, PC3 cells 
treated with rutin nanoemulsion showed con-
siderable increase in ROS intensity in a dose-
dependent manner as compared to untreated 
cells. The results of quantitative measurement 
of ROS level showed that 5 µM of rutin 
nanoemulsion induced 148.56 % (p < 0.05) 
enhancement in ROS production as compared 
to control. Moreover, ROS production was in-
creased by 207.57 % (p < 0.05) at 10 µM of 
rutin nanoemulsion when compared to un-
treated cells (Figure 5B). During apoptosis, 
ROS are produced by mitochondria which in-
crease the mitochondrial membrane permea-
bility and lead to the apoptotic phenotype 
(Fleury et al., 2002). ROS are more reactive 
than molecular oxygen which may be associ-
ated with the activation of signal molecules 
and destabilization of mitochondrial mem-
brane inducing the release of apoptotic agents 
resulting in toxicity to cancer cells (Chibber 
et al., 2012). Our results clearly stated that ru-
tin nanoemulsion provoked cells’ death by in-
ducing ROS production.  
 
 
Figure 4: Effect of rutin nanoemulsion on percent cells viability and cell morphology of human prostate 
carcinoma PC3 cell line. (A) Morphological view of live & dead cells treated with 2, 5, 10, 15 and 25 µM 
concentration of rutin nanoemulsion. Scale bar=100 μm. (B) Percent cell viability of PC3 cells measured 
by a MTT assay at 24 h as mentioned in the experimental part. Values are expressed as mean ± SEM 
of at least three independent experiments, *p < 0.05 as compared with their respective control
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Figure 5: Effect of rutin nanoemulsion on intracel-
lular ROS level in comparison to untreated cells 
against human prostate carcinoma PC3 cell line. 
(A) Photomicrographs showing intracellular ROS 
generation in PC3 cells induced by 5 and 10 µM 
concentration of rutin nanoemulsion after 12 h in-
cubation and stained with DCFH-DA. Scale 
bar=100 μm. (B) Graph showing extent of ROS 
generation expressed as the percentage of fluo-
rescence intensity relative to the control. Values 
are expressed as mean ± SEM of at least three 
independent experiments, *p < 0.05 as compared 
with their respective control 
 
 
Rutin nanoemulsion induces apoptosis  
The treatment by rutin nanoemulsion 
caused an increased number of apoptotic cells 
over the control cells. Morphology of treated 
cells suggested that the mode of action of 
nanoemulsion against tumor cells was apop-
tosis. The morphological properties such as 
cell shrinkage, nuclear fragmentation and 
condensation of chromatin forming apoptotic 
bodies were clearly proved (Ouyang et al., 
2012). The results of quantitative measure-
ment of apoptotic cells showed that 5 µM of 
rutin nanoemulsion induced 19 % (p < 0.05) 
apoptotic cells as compared to control. More-
over, percent apoptotic cells were increased 
by 33 % (p < 0.05) at 10 µM of compound 
when compared to untreated cells (Figure 
6B). A previous study has shown that a nano-
emulsion system incorporating both lycopene 
and gold nanoparticles significantly induced 
early apoptosis in HT-29 colon cancer cells 
(Huang et al., 2015). Similarly, rutin flavo-
noid has shown cytotoxicity against leukemia, 
multiple myeloma and melanoma cell lines in 
vitro (Ikeda et al., 2015). A previous study has 
shown that rutin inhibited human leukemia tu-
mor growth in a murine xenograft model sys-
tem (Lin et al., 2012). Further, in vitro study 
also revealed the apoptotic effect of rutin in 
neuroblastoma LAN-5 cell line (Chen et al., 
2013). In conclusion, the optimized nano-
emulsion of rutin showed good thermody-
namic stability with significant improvement 
in the drug release profile as compared to ru-
tin suspension. The nanoemulsion system of 
rutin bioactive was found to be more effica-
cious against prostate cancer cell line at very 
low concentration when compared to pure ru-
tin. Moreover, bio-distribution studies as well 
as in vivo anti-cancer efficacy studies on ani-
mal models of cancer are desired to explore 
the anticancer potential of rutin nanoemul-
sion. 
 
 
Figure 6: Quantitative measurement of apoptotic 
cells in human prostate carcinoma PC3 cell line. 
(A) PC3 cells were treated with 5 and 10 µM con-
centration of rutin nanoemulsion and stained with 
DAPI. Scale bar=100 μm. (B) Representative 
graphs showing the numerical data of the percent 
apoptotic cells against the concentration of rutin 
nanoemulsion. Values are expressed as mean ± 
SEM of at least three independent experiments, 
*p < 0.05 as compared with their respective con-
trol. 
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